Novo Nordisk’s Ozempic Gets FDA Approval

Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D and CKD. Novo Nordisk said its drug is the “most broadly indicated” GLP-1RA in its class.
Novo Nordisk's Ozempic Gets FDA Approval as Kidney-Disease Treatment
Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, the company said Tuesday.
US FDA Approves Novo Nordisk's Ozempic to Cut Risk of Diabetic Kidney Disease Progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Novo Nordisk’s Ozempic named in latest Medicare price negotiations
The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.
FDA approves Novo Nordisk’s diabetes drug Ozempic for chronic kidney disease, expanding its use
Ozempic's expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.
Novo Nordisk says it has not yet posted details about new CagriSema trial
Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...
GlobalData on MSN3d
Novo Nordisk reports topline data from Phase Ib/IIa trial of weight loss therapy
Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...
Hosted on MSN10mon
New Weight Loss Pill More Effective Than Ozempic, Tests Find
It's important to note that the sample size of the Phase 1 trial is ... investors are enthusiastic about the very early results, sending Novo Nordisk stock rising as much as 8.3 percent, making ...
BioWorld5d
Novo weight-loss data roll out; Veru ‘leans’ in
As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...
GlobalData on MSN10d
Novo Nordisk’s high-dose Wegovy increases weight loss and remains safe
Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable.
Outsourcing-pharma2d
Novo Nordisk’s next-generation obesity drug shows promise in early clinical trials
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...